{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21"],"submitter":["Akhavan B"],"pubmed_abstract":["<h4>Background</h4>Since 2022, the global epidemiology of Mpox (MPXV) has transformed, with Clade IIb driving widespread transmission in non-endemic regions and Clade I resurging across Central Africa. Genomic adaptations, such as APOBEC3 mutations, and increasing human-to-human transmission have raised public health alarms. This review synthesizes the latest evidence on Clade I and Clade II MPXV outbreaks from 2022 to 2024, with an emphasis on geographic expansion, demographic disparities, and systemic response gaps.<h4>Methods</h4>A comprehensive literature search was conducted between September and December 2024 using PubMed, CDC, WHO, and ECDC databases. Studies were included if they reported primary data on Clade I or Clade II MPXV epidemiology. Gray literature, including public healt"],"journal":["One health (Amsterdam, Netherlands)"],"pagination":["101232"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12538092"],"repository":["biostudies-literature"],"pubmed_title":["From forest to frontline: A comprehensive review of Mpox's global leap and viral evolution (2022-2024)."],"pmcid":["PMC12538092"],"pubmed_authors":["Alkhouri S","To W","Batra K","Akhavan B","Ahmed AB"],"additional_accession":[]},"is_claimable":false,"name":"From forest to frontline: A comprehensive review of Mpox's global leap and viral evolution (2022-2024).","description":"<h4>Background</h4>Since 2022, the global epidemiology of Mpox (MPXV) has transformed, with Clade IIb driving widespread transmission in non-endemic regions and Clade I resurging across Central Africa. Genomic adaptations, such as APOBEC3 mutations, and increasing human-to-human transmission have raised public health alarms. This review synthesizes the latest evidence on Clade I and Clade II MPXV outbreaks from 2022 to 2024, with an emphasis on geographic expansion, demographic disparities, and systemic response gaps.<h4>Methods</h4>A comprehensive literature search was conducted between September and December 2024 using PubMed, CDC, WHO, and ECDC databases. Studies were included if they reported primary data on Clade I or Clade II MPXV epidemiology. Gray literature, including public healt","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-04T16:15:07.905Z","creation":"2026-05-13T14:24:24.19Z"},"accession":"S-EPMC12538092","cross_references":{"pubmed":["41127628"],"doi":["10.1016/j.onehlt.2025.101232"]}}